Basic Information
| LncRNA/CircRNA Name | ESRPS-AS |
| Synonyms | 1810019D21Rik |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, RNA-seq, western blot etc. |
| Sample | cell lines (M28N2, M27H4, M6, M6C) |
| Expression Pattern | up-regulated |
| Function Description | ESRPs were shown previously to have a dual role in carcinogenesis. Both gain and loss have been associated with poor prognosis in human cancers, but the mechanisms regulating expression are not known. Indepth analyses indicate that coordinate overexpression of Esrp2 and Esrp2-as inversely correlates with DNA methylation. Using the Kaplan-Meier plotter survival analysis tool,we could confirm that high ESRP2 mRNA levels reduce the fraction of relapse-free survival, overall survival, and distant metastasis-free survival of breast cancer cases analyzed together or when cases were subdivided into breast cancer subtypes. |
| Pubmed ID | 28759043 |
| Year | 2017 |
| Title | Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and lncRNA Esrp2-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer |
External Links
| Links for ESRPS-AS | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |